/TRYPF

TRYPF Stock - Tryp Therapeutics Inc.

Q: What is the analyst price target for TRYPF?

Analyst price target information is not currently available for TRYPF.

Q: What is TRYPF's market cap?

Market capitalization information is not currently available for TRYPF.

Healthcare|Biotechnology|OTC

$0.06+32.24%

+$0.01 (+32.24%) • May 1

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.06

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TRYPF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-1.28

52W High$0.09

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-4,701,745	$-7,229,913	$-6,310,570	$-422,617
Net Income	$-5,267,073	$-7,494,966	$-8,254,709	$-422,617
Net Margin	N/A	N/A	N/A	N/A
EPS	$-0.05	$-0.10	$-0.12	$-0.01

Company Overview

Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 and TRP-8803 for fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. The company has an agreement with the Calvert Labs to design and execute exploratory studies related to psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was incorporated in 2019 and is based in Kelowna, Canada.

Visit Website

Earnings History & Surprises

TRYPF

Beat Rate

Last 4 quarters

Avg Surprise

-58.3%

EPS vs Estimate

Beats / Misses

0/2

2 met exactly

Latest EPS

$-0.01

Q1 2024

EPS Surprise History

Q3 22

No data

Q4 22

No data

Q4 22

-200.0%

$-0.03vs$-0.01

Q1 23

No data

Q2 23

No data

Q3 23

No data

Q4 23

No data

Q1 24

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Feb 29, 2024	—	$-0.01	—	—
Q4 2023	Nov 30, 2023	—	$-0.01	—	—
Q3 2023	Aug 31, 2023	—	$-0.01	—	—
Q2 2023	May 31, 2023	—	$-0.01	—	—
Q1 2023	Feb 28, 2023	—	$-0.01	—	—
Q4 2022	Dec 13, 2022	$-0.01	$-0.03	-200.0%	✗ MISS
Q4 2022	Nov 30, 2022	—	$-0.01	—	—
Q3 2022	Jul 27, 2022	—	$-0.01	—	—
Q2 2022	Apr 29, 2022	$-0.03	$-0.03	0.0%	= MET
Q1 2022	Jan 28, 2022	$-0.05	$-0.05	0.0%	= MET
Q4 2021	Dec 22, 2021	$-0.03	$-0.04	-33.3%	✗ MISS
Q3 2021	Jul 28, 2021	—	$-0.03	—	—
Q2 2021	Apr 29, 2021	—	$-0.04	—	—
Q1 2021	Jan 29, 2021	—	$-0.01	—	—
Q4 2020	Dec 8, 2020	—	—	—	—